|
nervous system disorder
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Studies must have described the planning/implementation of BCS targeting PA in adults with neurological disorders, with interventions delivered by a HCP.
|
30496560 |
2020 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
Biomarker
|
disease |
BEFREE |
Drug delivery and therapeutic challenges of gliclazide, a BCS class II drug used in type 2 diabetes mellitus (T2DM) can be overcome by exploring smarter carriers of second-generation nanocrystals (SGNCs).
|
31758056 |
2019 |
|
Fatigue
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusion:</b> Our results suggest that BCS1L and complex III in mitochondrial mononuclear cells are potential biomarkers and feasible therapeutic targets for acute XRT-induced fatigue in this clinical population.
|
31410061 |
2019 |
|
Breast Phyllodes Tumor
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We recommend application of ART for such patients but the role of ART in patients with borderline and malignant PTB treated with BCS and with surgical margin < 1 cm remains uncertain.
|
30521986 |
2019 |
|
Major Depressive Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among women with DCIS, those at risk for MDD were more likely to receive BCS (adjusted odds ratio [AOR] 2.04, 95% CI 1.04-4.00, p = 0.04) or mastectomy (AOR 1.88, 95% CI 0.91-3.86, p = 0.09) compared to BCS + RT.
|
30406869 |
2019 |
|
Alcohol Use Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study attempted to devise a brief cognitive screen (BCS- AUD) for alcohol use disorders.
|
29540913 |
2018 |
|
Mental disorders
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Using the S-PTD, delirium was identified in 72 (25.0%), while an expert neuropsychiatric examination, based on DSM-5 identified delirium in 75 (26.0%) patients.
|
30314583 |
2018 |
|
Blast Phase
|
0.010 |
Biomarker
|
disease |
BEFREE |
MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
|
30431598 |
2018 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The PTD modified paclitaxel anti-resistant liposomes may provide a promising strategy for treatment of the drug-resistant non-small cell lung cancer.
|
28480778 |
2018 |
|
Chorioamnionitis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Gene expression of 50 ABC transporters was assessed using TaqMan® Human ABC Transporter Array, in preterm human placentas without (PTD; n=6) or with histological chorioamnionitis (PTDC; n=6).
|
29402780 |
2018 |
|
Delirium
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using the S-PTD, delirium was identified in 72 (25.0%), while an expert neuropsychiatric examination, based on DSM-5 identified delirium in 75 (26.0%) patients.
|
30314583 |
2018 |
|
HIV Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Rilpivrine is BCS class II drug used for treatment of HIV infection.
|
29869305 |
2018 |
|
Leishmaniasis, Visceral
|
0.010 |
Biomarker
|
disease |
BEFREE |
Buparvaquone (BPQ), a hydroxynapthoquinone with in vitro activity in the nanomolar range, failed to clinically translate as a viable treatment for visceral leishmaniasis due to its poor oral bioavailability limited by its poor aqueous solubility (BCS Class II drug).
|
29762040 |
2018 |
|
Post-Traumatic Stress Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The mediating effects of seeking social support and engaging in wishful thinking on the PTSD symptoms and PTD link were, however, non-significant.
|
30319492 |
2018 |
|
Supraventricular tachycardia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To synthesize the prevalence of CALR mutations according to the different types (i.e., Budd-Chiari syndrome [BCS] and portal vein thrombosis [PVT]) and characteristics (i.e., with and without myeloproliferative neoplasms [MPNs] and JAK2V617F mutation) of SVT patients.
|
29803161 |
2018 |
|
Secondary glaucoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, because secondary glaucoma is not a feature of BCS1, we speculate that the onlay graft may have reduced aqueous outflow by compression of the thinned sclera.
|
30115710 |
2018 |
|
Portal Vein Thrombosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To synthesize the prevalence of CALR mutations according to the different types (i.e., Budd-Chiari syndrome [BCS] and portal vein thrombosis [PVT]) and characteristics (i.e., with and without myeloproliferative neoplasms [MPNs] and JAK2V617F mutation) of SVT patients.
|
29803161 |
2018 |
|
Carcinoma of Male Breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Since overall prognosis and systemic therapy recommendations for MBC are similar to breast cancer in women, we describe the first case of MBC treated with BCS and IORT.
|
28597470 |
2018 |
|
Malignant neoplasm of male breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Since overall prognosis and systemic therapy recommendations for MBC are similar to breast cancer in women, we describe the first case of MBC treated with BCS and IORT.
|
28597470 |
2018 |
|
Ehlers-Danlos syndrome 6B
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Brittle cornea syndrome (BCS1 OMIM #229200, BCS2 #614170) is a rare autosomal recessive condition characterised by diffuse thinning and fragility of the cornea.
|
30115710 |
2018 |
|
Regular astigmatism - corneal
|
0.010 |
Biomarker
|
disease |
BEFREE |
We describe a 9-year-old girl with BCS1, already blind in one eye following trauma, who had a 14 mm diameter corneoscleral onlay graft to her contralateral eye to reduce gross irregular corneal astigmatism and potentially to reduce further risk from accidental injury.
|
30115710 |
2018 |
|
Arteriovenous graft
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report a case of vein rupture by Arrow-Trerotola percutaneous thrombolytic device (Trerotola PTD) during a treatment of thrombosed arteriovenous graft (AVG).
|
29529963 |
2018 |
|
Invasive carcinoma of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Women under age 70 with invasive breast cancer who underwent BCS from 2004 to 2014 were analyzed.
|
30083949 |
2018 |
|
Chronic myeloproliferative disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
|
30431598 |
2018 |
|
Early-Stage Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
After discussion among our multidisciplinary tumor board, we felt this patient to be suitable for BCS and IORT given his age, favorable tumor subtype, size, and clinically early stage breast cancer.
|
28597470 |
2018 |